周一，BMO Capital Markets维持了对临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)的乐观立场，重申了"优于大市"评级和95.00美元的目标价。这一背书紧随Merus宣布开始在一项关键的3期试验（名为LiGeR-HN1）中给第一位患者用药。该研究正在评估petosemtamab（也称为peto）与pembrolizumab联合用于治疗此前未经治疗的头颈部癌症患者的疗 ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

荷兰乌特勒支 - 临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)宣布启动一项3期临床试验，研究新型癌症治疗药物petosemtamab与pembrolizumab联合用于复发或转移性头颈部鳞状细胞癌(r/m HNSCC)患者的治疗。LiGeR-HN1试验已完成首例患者给药，该试验将比较这种联合疗法与单独使用pembrolizumab作为一线治疗的疗效和安全性。 Petosemta ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

无论肿瘤的PD-L1表达如何，Opdivo和Keytruda都在这两种适应症中获得了批准。然而，FDA表示，越来越多的证据表明，PD-L1的表达可以作为药物在这一人群中疗效的预测性生物标志物。

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

结直肠癌（CRC）是一种常见的恶性肿瘤，在所有癌症中的发病率（6.1%）位居第三，死亡率（9.4%）居第二位。由于大肠癌的 ...